Rhabdomyosarcoma Clinical Trials

MSK Kids conducts clinical trials of potentially more effective therapies for rhabdomyosarcoma. Participants have the chance to receive a new treatment early in its development. Some of our clinical trials are evaluating new drugs. Others are assessing existing drugs and drug combinations used in adults with cancer that may be useful in young people with rhabdomyosarcoma.

Your child’s care team will let you know if your child can participate in a clinical trial. The decision to enroll is entirely voluntary. The study team will explain the benefits and risks of the study to you so you can make an informed decision.

and/or
2 Clinical Trials found
A Phase I Study of Codrituzumab in Children and Young Adults with Recurrent or Persistent Solid Tumors
The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).
New York City
A Phase III Study of Different Treatments for People Newly Diagnosed with Very Low-Risk and Low-Risk Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues in the body. Researchers in this study are comparing different chemotherapy-based treatments for children and young adults with very low-risk RMS, low-risk RMS, and RMS with DNA mutations, with treatment tailored to the predicted aggressiveness of each patient's cancer. The standard chemotherapy drugs participants will receive include vincristine, dactinomycin, and cyclophosphamide.
New York City